Literature DB >> 15115309

Association between insulin resistance and GAD65-autoantibody levels--a pilot study in an adult non-diabetic population.

M H Hedman1, O Rolandsson, E Hägg, L Mincheva-Nilsson, B Lindahl.   

Abstract

The aim of this pilot study was to investigate any association between insulin resistance (IR) and serum levels of autoantibodies against the glutamic acid decarboxylase (GAD65Ab) among adult non-diabetic subjects. Based on calculations of IR using the IR homeostasis model in a Swedish adult non-diabetic population (n = 756) participating in the WHO MONICA-study, an insulin sensitive group (n = 54, M/F:27/27) and an insulin resistant group (n = 46 M/F:24/22) were identified. Serum from the subjects were analysed for the presence of GAD65Ab. There was no significant difference in GAD65Ab levels between the groups. However, there was a correlation between IR and serum GAD65Ab within the insulin sensitive group (Spearman rho 0.4, p < 0.01). Our observation could indicate that IR could serve as an initiator or a progression factor in the autoimmune process in subjects predisposed to autoimmunity. This finding will be further investigated in a larger study including subjects with a continuum of IR.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15115309     DOI: 10.1080/08916930310001607943

Source DB:  PubMed          Journal:  Autoimmunity        ISSN: 0891-6934            Impact factor:   2.815


  2 in total

1.  β-cell autoimmunity in overweight non-diabetic youth: any implications?

Authors:  Ingrid M Libman; E Barinas-Mitchell; S Marcovina; F Bacha; T Hannon; H Tfayli; S J Lee; S Bansal; R Robertson; S Arslanian
Journal:  Pediatr Diabetes       Date:  2010-09-07       Impact factor: 4.866

Review 2.  The effect of bariatric surgeries on nonalcoholic fatty liver disease.

Authors:  Mazen Hassanian; Amnah Al-Mulhim; Atheer Al-Sabhan; Shaden Al-Amro; Fahad Bamehriz; Ayman Abdo; Hisham Al Khalidi; Tamader A Aldoheyan
Journal:  Saudi J Gastroenterol       Date:  2014 Sep-Oct       Impact factor: 2.485

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.